[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obstructive-sleep-apnea-osa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obstructive-sleep-apnea-osa":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,67,0,25,[9,57,88,134,159,182,204,231,255,288,318,339,367,392,421,441,464,493,520,540,563,599,623,652,680],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100652959","screening-for-obstructive-sleep-apnea-in-high-risk-patients-in-a-danish-rural-population-a-pilot-feasibility-study-100652959",false,"NCT07778121","Screening for Obstructive Sleep Apnea in High-risk Patients in a Danish Rural Population: A Pilot Feasibility Study","Screening for Obstructive Sleep Apnea in High-risk Patients in a Danish Rural Population","Inclusion Criteria:\n\n* Age 18 years or above\n* Diagnosed with type 2 diabetes mellitus\n* Resident in Region Zealand, Denmark\n* Understand and speak Danish\n\nExclusion Criteria:\n\n* Previously undergone surgery for OSA\n* Currently or within the last month used treatment for OSA such as CPAP, sleep position trainer, mandibular advancement devices etc.\n* Having an Implanted Cardioverter Defibrillator (ICD)\n* Clinically suspected of a sleep disorder other than OSA that might compromise the intended purpose of the devices",true,"ALL","18 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background:\n\nObstructive sleep apnea (OSA) is a sleep disorder characterized by recurrent collapse of the upper airway during sleep, resulting in intermittent hypoxia and fragmented sleep. The condition is more prevalent among individuals with hypertension, atrial fibrillation, type 2 diabetes, and other chronic diseases compared with the general population. Evidence indicates that untreated OSA is associated with adverse health outcomes, whereas treatment of OSA provides significant clinical benefits. However, a substantial proportion of individuals with OSA remain undiagnosed, highlighting the need to improve detection and reduce underdiagnosis.\n\nDevices currently used to diagnose OSA are not suitable for screening; however, newer alternatives may be appropriate.\n\nThe study:\n\nThis study is a pilot feasibility study. All participants will undergo an interview and examination at a baseline visit and will subsequently use OSA testing devices at home for three consecutive nights. The study includes a questionnaire assessing participants' experience with the devices and technology in general. The objective of this study is to test the feasibility of conducting a study in which adult participants with type 2 diabetes undergo three different home sleep apnea tests over three nights, including issues to be optimized in a subsequent main\u002Fdefinitive study.\n\nThe main study aims to assess the diagnostic agreement between the devices and will be registered independently.",[28,29],"Type 2 Diabetes","Obstructive Sleep Apnea (OSA)",[31,32,33,34,35,36,28,37,38,39,40,41,42,43],"Home Sleep Apnea Test","HSAT","NightOwl","SleepImage","OSA","Obstructive Sleep Apnea","Peripheral Arterial Tonometry","Cardiopulmonary coupling","Screening","Feasibility","Pilot","Nox T3","Cardiorespiratory Monitor","RECRUITING","2026-08-20",{"date":47,"type":48},"2026-08-21","ACTUAL",{"date":50,"type":48},"2025-10-20",{"date":52,"type":22},"2026-10-01",{"name":54,"class":55},"Zealand University Hospital","OTHER",1,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100645057","phase-4-a-comparative-effectiveness-study-of-positive-airway-pressure-pap-therapy-dental-device-and-atomoxetine-oxybutynin-for-treatment-of-obstructive-sleep-apnea-in-adults-100645057","NCT07679282","A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults","Comparative Effectiveness of Positive Airway Pressure Therapy, Dental Device, and Atomoxetine-Oxybutynin for Sleep Apnea: the ADAPT-OSA Study","ADAPT-OSA","Inclusion Criteria:\n\n* Obstructive sleep apnea (AHI \\>\u002F= 5 per hour), diagnosed in the past 6 months\n* Two or more of the following symptoms: snoring, fragmented sleep, witnessed apneas, or daytime sleepiness\n* Willingness\u002Fability to use any of the 3 treatments for OSA (PAP, dental device, or atomoxetine-oxybutynin)\n* Health insurance of any type\n\nExclusion Criteria:\n\n* Prior treatment for OSA in past year\n* Central sleep apnea or narcolepsy\n* Contraindication for dental device (temporomandibular joint problems, severe periodontal disease, insufficient dentition)\n* Heart failure with reduced ejection fraction of \\\u003C\u002F= 45%\n* Active coronary artery disease (angina or infarction within 3 months of enrollment)\n* Current untreated depression\n* Untreated narrow angle glaucoma\n* Untreated hypothyroidism\n* Clinically significant gastric retention\n* Clinically significant urinary retention\n* History of liver disease\n* Seizure disorder\n* Pregnant or nursing, or plans to become pregnant within the year\n* Concomitant medication use that is incompatible with atomoxetine or oxybutynin\n* Participation in another clinical study with an investigational product",{"count":66,"type":22},2400,[68],"PHASE4","Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.",[29],[72,73,74,75,76],"Sleep apnea treatments","Dental device for sleep","Positive airway pressure","Atomoxetine-oxybutynin","Comparative effectiveness","NOT_YET_RECRUITING","2026-08-11",{"date":80,"type":48},"2026-08-13",{"date":82,"type":22},"2026-09-01",{"date":84,"type":22},"2032-05-01",{"name":86,"class":55},"Sairam Parthasarathy",4,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":133},"100643054","phase-2-dreamzz--dronabinol-and-acetazolamide-medication-for-sleep-apnea-zz-dose-confirmation-crossover-study-for-ihl-42x-in-subjects-with-obstructive-sleep-apnea-100643054","NCT07635563","DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.","Phase II, Randomized, Double-Blind, Multidose Crossover Clinical Trial to Determine the Safety and Efficacy of IHL-42X in Subjects With Obstructive Sleep Apnea","DReAMzz","Inclusion Criteria\n\nParticipants must satisfy all the following criteria at screening unless otherwise stated:\n\n1. Aged ≥18 and ≤65 years of age at the time of consent.\n2. Two screening PSG findings confirmed on central over-read that both must meet the below criteria:\n\n   1. AHI4 ≥5\n   2. ≤25% central or mixed apneas out of total AHI\n   3. no Cheyne-Stokes respiration\n   4. total sleep time ≥ 4 hours in each PSG\n   5. \\\u003C 30 periodic leg movement disorder arousals per hour.\n3. A difference in AHI4 of ≤15 between screening PSG 1 and screening PSG 2.\n4. A PROMIS-SRI 8a score of \\>16.\n5. Intolerant or non-compliant to PAP, or has refused PAP after physician recommendation. Participants will be identified as intolerant or non-compliant to PAP devices by the following criteria (NB: OSA diagnosis must be entered in participant medical history):\n\n   1. Participants are regarded as PAP-non-compliant if they do not use PAP for ≥ 4 hours for at least 63 nights during consecutive 90-day period based on data collected from the PAP device (e.g., SD storage cards) and\u002For a cloud-based repository of PAP device data.\n   2. Participants are regarded as PAP-intolerant if they are former PAP users, i.e., a PAP device that they have not used for \\>90 days, have tried PAP and not continued to use it or refusal of PAP after prior positive sleep study or prior refusal of provider recommended sleep study due to unwillingness to consider PAP.\n\n   NB: Participants will have the benefits and risks of PAP explained at screening, including that PAP is standard of care for OSA. Participants also have the option to withdraw from the study at any time if he\u002Fshe elects to be treated with PAP or other alternative therapy such as an oral appliance or surgery.\n6. Must agree not to take any form of cannabis or cannabinoid with the exception of the IP, or any other illicit or recreational drug while participating in this study.\n7. A female participant of childbearing potential must agree to at least one approved highly effective method of contraception. Approved methods of contraception include the following:\n\n   1. Intra-uterine device in place for at least 3 months prior to Day 1 through to 10 days following the last dose of the study drug.\n   2. Stable hormonal contraceptive which includes oral, intravaginal, intrauterine, transdermal, injectable, or implantable methods of hormonal contraception for at least 3 months prior to Day 1 through to 10 days after the last dose of the study drug.\n\n      NB: Barrier method (condom or diaphragm) is not considered 'highly effective' for the purpose of this study and should be used in combination with one of the approved highly effective methods listed above.\n\n      A female will not be considered of childbearing potential if:\n   3. 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \\> 40 mIU\u002Fml.\n   4. Undergone bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to Day 1.\n8. A male participant must agree to use at least 1 approved method of contraception (or as required by local regulations) while engaging in sexual activity from study Day -1 through EOS follow-up and\u002For up to 10 days following the last administration of the study drug. Male participants must not donate sperm during this same period. Approved methods of contraception include the following:\n\n   1. Barrier method (condom) from date of consent through to 10 days after the final dose of the study drug.\n   2. Surgical sterilization (vasectomy) at least 6 months prior to Day 1 with proof of azoospermia.\n9. Voluntarily written consent to participate in the study and be willing and able to participate in all scheduled visits, treatment plans, tests, and other study procedures according to the protocol.\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if they satisfy any of the following criteria at screening, unless otherwise stated:\n\n1. Body mass index (BMI) \\>40 kg\u002Fm2 (men) and \\>42 kg\u002Fm2 (women).\n2. Diagnosed obesity hypoventilation syndrome or hypercapnia.\n3. PAP-compliant, defined by use of PAP for ≥4 hours for at least 63 nights during the consecutive 90-day period.\n4. Current use of custom-made oral appliances (mandibular advancement device, tongue retaining device, or mouth guard) or hypoglossal nerve stimulation devices. Devices must not be used for the duration of the study.\n5. Maxillomandibular advancement, upper airway, or bariatric surgery within the last 6 months prior to first administration of the study drug; or participants who are planning surgical treatment.\n6. Have commenced glucagon-like peptide-1 receptor agonist therapy within the last 6 months.\n7. Use of benzodiazepines, sedative-hypnotics or stimulants (Anatomical Therapeutic Chemical \\[ATC\\] N06B, N05C, N05BA, N03AE, and N01AF categories) to treat insomnia, OSA, and other sleep disorders, or other disorders that require the drug to be taken prior to sleep.\n8. Use of other prescription medications to treat insomnia.\n9. Pierre Robin, Treacher Collins, or other craniofacial malformation syndrome, or grade ≥3 tonsillar hypertrophy.\n10. Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator.\n11. Known allergic or other severe reaction to cannabis products with previous use.\n12. Known allergic reaction to sesame oil.\n13. Known allergic reaction to acetazolamide.\n14. Pregnant or breastfeeding.\n15. Current illicit drug abuse (within the last 6 months prior to screening); \"abuse\" has some subsets that are objective and some that require investigator judgement; questions should be discussed with the medical monitor or with the sponsor\n\n    1. An objective subset includes consumption of substances that are \"illicit\", i.e., not legal per local laws\n    2. Investigator judgement is expected for legally marketed products ingested for other than the approved indication(s)\n    3. Participants who test positive to THC should be screen failed and can be considered for rescreening after a \\>6-week washout period. Participants can only be rescreened once. Positive test results for all other substances shall be reviewed by the investigator and participants shall only be screen failed if the investigator believes the use of the substance may be clinically significant with regards to the participant's safe participation in this study or may confound this study's findings.\n16. Severe depression, defined as a score of ≥30 on the Major Depression Inventory (MDI) questionnaire.\n17. Severe anxiety, defined as score of \\>15 on the General Anxiety Disorder-7 (GAD-7) questionnaire.\n18. Any of the following co-morbid conditions (NB: clarification on co-morbidities and inclusion\u002Fexclusion criteria may be discussed with the medical monitor and\u002For sponsor):\n\n    1. Severe psychiatric disorder that might be aggravated or exacerbated by dronabinol's potential to cause anxiety\u002Fnervousness, depersonalization, hallucination, etc.\n    2. Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator.\n    3. Cardiac dysfunction and\u002For its treatment that might augment dronabinol's potential to cause tachycardia or vasodilation.\n    4. Marked hepatic dysfunction as defined by elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 × the upper limit of normal (ULN), that would reduce dronabinol metabolism.\n\n    i. One retest per participant is permitted at the discretion of the investigator; the participant may continue if BOTH repeat transaminase levels are within acceptable range (i.e., less than 3 × ULN).\n\n    e. Current or history of encephalopathy or cirrhosis Child-Pugh category B or C (see Appendix 8) since acetazolamide can increase blood ammonia levels precipitating a bout of hepatic encephalopathy.\n\n    f. Marked renal dysfunction that would reduce acetazolamide excretion, including eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m2, as determined using the National Kidney Foundation calculator (https:\u002F\u002Fwww.kidney.org\u002Fprofessionals \u002Fkdoqi\u002Fgfr\\_calculator) and instructions in Appendix 9.\n\n    g. Hypokalemia (low blood potassium), hyponatremia (low blood sodium), hyperchloremic acidosis, and\u002For adrenal insufficiency that might be aggravated or exacerbated by acetazolamide's activity as a carbonic anhydrase inhibitor.\n19. Known CYP2C9 poor metabolizers (NB: this is based on medical history and does not need to be tested genetically).\n20. Other ongoing condition(s) that the investigator considers may be clinically significant with regards to the participant's safe participation in this study or may confound this study's findings; any consideration should be discussed with the medical monitor or with the sponsor (such as known alcohol abuse).\n21. Shift workers whose shift pattern has the potential to disrupt sleep patterns.\n22. Participation in any other interventional studies involving investigational or marketed products within 30 days or 5.5 half-lives, whichever is longer, prior to screening.","65 Years",{"count":98,"type":22},120,[100],"PHASE2","The goal of this randomized, double-blind, multi-dose crossover clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnea.\n\nThe primary endpoint is: Change in AHI4 at the end of each treatment period compared to baseline (each treatment period is 28 days).\n\nThe study will consist of three separate four-way crossover dose-comparison studies each comparing three dose strengths of IHL-42X to placebo. The double-blind four-way crossover will be conducted according to a Williams design. Each of the crossover studies will test different doses of dronabinol in combination with a distinct, set dose of acetazolamide. In total, nine different combinations of dronabinol and acetazolamide formulated as IHL-42X will be tested in the study. The optimal dose strength will be selected based on safety and efficacy over a 4-week treatment period.",[29],[35,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124],"Obstructive sleep apnea","Obstructive sleep apnoea","CPAP","Cannabinoid","IHL-42X","Incannex","Dronabinol","THC","Aceazolamide","ACZ","AHI","PSG","Polysomnography","PAP","FOS-Q","FOSQ","PROMIS","PGI","ESS","REM","Phase II",{"date":80,"type":48},{"date":127,"type":48},"2026-07-21",{"date":129,"type":22},"2027-05",{"name":131,"class":132},"Incannex Healthcare Ltd","INDUSTRY",14,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":56},"100630947","personalised-active-self-management-of-sleep-apnea-program-100630947","NCT07494292","Personalised Active Self-management of Sleep Apnea Program","A Personalised Active Self-management of Sleep Apnea Program (PASS) to Improve Positive Airway Pressure Treatment Uptake and Adherence: A Pilot Randomized Controlled Trial","PASS","Inclusion Criteria:\n\n* Aged 18 years and above\n* Newly diagnosed with OSA (diagnosis made within the past year)\n* Newly started or not yet started Positive Airway Pressure (PAP) treatment, with a treatment duration of less than 6 months\n* Physically inactive (self-reported moderate physical activity per week of \\\u003C150 minutes)\n* Overweight (BMI≥23 kg\u002Fm2)\n* Mentally, cognitively, and physically fit to join the trial as determined by the doctor in charge and responsible clinical investigators\n* Able to speak, read, and write Chinese\n* Willing to complete the questionnaires and assessments\n* Has a smartphone\n\nExclusion Criteria:\n\n* Clinically significant psychiatric disorder\n* Use of prescription drugs or clinically significant drugs affecting sleep.",{"count":143,"type":22},60,[25],"This study is to assess the feasibility and acceptability of the PASS in patients with OSA. Second, the study examines its effectiveness in improving PAP uptake and adherence, self-efficacy in self-care, changes in health-related habits, and health outcomes. We also assess the facilitators and barriers to implementing the PASS.\n\nThis is a two-group pilot randomized controlled trial (n=60) with a 4-month follow-up. Subjects assigned to the intervention group will receive a 4-month Personalized and Adaptive Sleep Support (PASS) program, a digital platform-based intervention. The 4-month program incorporates: i) a 20-minute brief motivational interviewing session; ii) a digital platform where users can view personalized OSA health-related videos and information, track their adherence to prescribed treatments, log their daily activities and dietary intake, and set personal health goals; and iii) continuous personalized chat-based messaging and phone call support. Participants in the control group will receive a 4-month general hygiene program, including (i) a 20-minute session, (ii) messaging, and (iii) phone call support.\n\nThe feasibility and acceptability of the PASS will be evaluated via semi-structured interviews at the 4-month follow-up. Self-administered questionnaires will be used at baseline and 4 months, and objective assessment tools (such as sleep tests) will be used at baseline and at the 4-month follow-ups. PAP adherence data will be downloaded from PAP machines (if available) for all subjects in both groups at baseline and at month 4.",[29],[148,35,149],"self-management","digital health","2026-08-04",{"date":152,"type":48},"2026-08-06",{"date":154,"type":22},"2026-08-03",{"date":156,"type":22},"2027-06-30",{"name":158,"class":55},"Hong Kong Metropolitan University",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":87},"100650207","study-on-the-management-of-comisa-100650207","NCT07743931","Study on the Management of COMISA","COMISA-PEC","Inclusion Criteria:\n\n* Adult patient diagnosed with COMISA, defined by an apnea-hypopnea index (AHI) ≥ 15 events\u002Fhour and an Insomnia Severity Index (ISI) score ≥ 15, newly diagnosed and naïve to CPAP therapy and daridorexant treatment (no treatment for \\> 5 years).\n* Prescription of continuous positive airway pressure (CPAP) therapy combined with a prescription of daridorexant.\n* Patient has provided informed consent to participate in the study.\n* Patient is affiliated with a national health insurance system.\n\nExclusion Criteria:\n\n* Severe hepatic impairment (contraindication to daridorexant treatment).\n* Refusal of CPAP therapy and\u002For refusal of daridorexant treatment.\n* Individuals covered under Articles L1121-5 to L1121-8 of the French Public Health Code.\n* Staff members who have a hierarchical relationship with the principal investigator.\n* Any patient who, in the opinion of the investigator, would be unable to comply with study procedures or the study schedule.","75 Years",{"count":168,"type":22},150,[25],"COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.",[29,172,173],"Insomnia","COMISA","2026-07-31",{"date":150,"type":48},{"date":177,"type":22},"2026-08",{"date":179,"type":22},"2029-02",{"name":181,"class":55},"University Hospital, Grenoble",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":200,"leadSponsor":202,"locationsCount":4},"100650273","cost-effectiveness-analysis-of-home-polysomnography-made-by-primary-care---sonopc-study-100650273","NCT07744880","Cost-effectiveness Analysis of Home Polysomnography Made by Primary Care - (SONOPC Study)","Cost-effectiveness Analysis of Home Polysomnography Made by Primary Care Compared to Standard Protocol in Health Public System in Brazil","SONOPC","Inclusion Criteria:\n\n* aged 18 years or older;\n* present clinical suspicion of OSA, confirmed by screening using the STOP-BANG and Epworth Sleepiness Scale questionnaires;\n* be receiving care at Basic Health Units (UBS), or be registered on the Central Regulation waiting list system for polysomnography (PSG);\n\nExclusion Criteria:\n\n* use of home oxygen therapy;\n* use of invasive or non-invasive mechanical ventilation;\n* use of a tracheostomy;\n* change of residence during the data collection period;\n* known allergy to materials used in sleep monitoring equipment.",{"count":143,"type":22},[25],"The goal of this randomized clinical trial is to assess the cost-effectiveness of a home polyssomnography made by primary care compared to standard protocol for diagnosing obstructive sleep apnea in both genders. Researchers will compare if a polyssomnography made by primary care is more cost-effective than standard protocol to see if this strategy decrease the wait time to get this exam in public health system in Brazil .\n\nParticipants will undergo diagnostic screening using the STOP-BANG and Epworth questionnaires; following the identification of apnea risk, they will be randomized into two groups: one group will undergo the examination via the health department's scheduling system, while the other will do so through primary health care services at the unit closest to their residence.",[29],[195,196],"cost effectiveness analysis","primary care","2026-07-29",{"date":150,"type":48},{"date":82,"type":22},{"date":201,"type":22},"2027-09-30",{"name":203,"class":55},"Escola Superior de Ciencias da Saude",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":56},"100649172","how-wall-squat-exercise-affects-blood-pressure-in-people-with-high-blood-pressure-and-treated-sleep-apnea-wallpress-100649172","NCT07730879","How Wall Squat Exercise Affects Blood Pressure in People With High Blood Pressure and Treated Sleep Apnea (WALLPRESS)","Acute Blood Pressure Responses to Isometric Wall Squat Exercise in Adults With Hypertension and CPAP-Treated Obstructive Sleep Apnea: A Randomized Crossover Trial","WALLPRESS","Inclusion Criteria:\n\n* 18-80 years old.\n* Diagnosis of hypertension and OSA confirmed by polysomnography or respiratory sleep study.\n* Apnea-Hypopnea Index (AHI) of at least 15 events per hour.\n* Treatment with CPAP for at least 3 months.\n\nExclusion Criteria:\n\n* Mean CPAP adherence \\\u003C4 hours\u002Fnight over the last month, documented by device download.\n* Heart failure.\n* Peripheral artery disease.\n* Atrial fibrillation.\n* Chronic obstructive pulmonary disease.\n* Chronic kidney disease.\n* History of acute coronary syndrome, stroke, or transient ischemic attack in the previous 12 months.\n* Relevant changes in antihypertensive or other cardiovascular pharmacotherapy in the previous 3 months.\n* Relevant changes in CPAP prescription in the previous 3 months.\n* Any contraindication to exercise according to contemporary ESC\u002FACSM recommendations (e.g. unstable angina).\n* Pregnancy or breastfeeding.\n* Neurological and\u002For orthopaedic conditions that could interfere with exercise (e.g. severe knee osteoarthritis, recent lower-limb surgery).\n* Inability to read, understand, or provide informed consent.","80 Years",{"count":214,"type":22},20,[25],"This study will look at whether a simple exercise called the isometric wall squat can help lower blood pressure in adults who have both hypertension and obstructive sleep apnoea treated with CPAP. Obstructive sleep apnoea is a condition in which breathing repeatedly stops or becomes shallow during sleep, and it is closely linked to high blood pressure. Although CPAP helps treat sleep apnoea, it usually lowers blood pressure only a little, so additional non-drug strategies may be useful.\n\nThe study will compare two situations in the same participants: one session of wall squat exercise and one non-exercise control session. Each participant will take part in both sessions, but the order will be random. This design helps the researchers compare blood pressure changes more fairly within the same person.\n\nParticipants will first attend a familiarization session, where the study procedures will be explained and the exercise intensity will be checked. After that, they will complete the two study sessions at home, during their usual CPAP treatment visits. The sessions will be separated by at least 48 hours and completed within one week. Both sessions will be scheduled at the same time of day to reduce the effect of normal daily changes in blood pressure.\n\nThe main result the researchers will measure is the average systolic blood pressure during the 12 hours after each session, using ambulatory blood pressure monitoring. This means blood pressure will be measured over time while the participant goes about normal daily activities. The researchers want to find out whether a single session of wall squat exercise produces a greater blood pressure reduction than simply resting without exercise.\n\nThis study may help improve understanding of whether isometric exercise can be a practical, low-cost, home-based option to support blood pressure control in people with hypertension and CPAP-treated obstructive sleep apnoea.",[218,29],"Hypertension",[220,221,222],"isometric exercise","wall squat","blood pressure","2026-07-28",{"date":197,"type":48},{"date":226,"type":22},"2026-07-30",{"date":228,"type":22},"2026-11-30",{"name":230,"class":55},"Aveiro University",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":239,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100596766","hypoglossal-nerve-stimulation-for-the-treatment-of-adult-obstructive-sleep-apnea-100596766","NCT07049744","Hypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea","Bilateral Hypoglossal Nerve Stimulation With the XII Medical HGNS System for the Treatment of Adult Obstructive Sleep Apnea Pilot Study","BEAT OSA","Inclusion Criteria:\n\n* Body Mass Index (BMI) ≤ 32 kg\u002Fm2\n* AHI of 15-50 events\u002Fhour\n* Central + mixed apnea index ≤ 25%\n* Participants who have either not tolerated, have failed or refused positive airway pressure (PAP)\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding.\n* Significant upper airway anatomic abnormalities\n* Hypoglossal nerve weakness\n* Central sleep apnoea condition\n* Significant positionally-dependent OSA.\n* Complete concentric patterns of soft palate collapse on DISE\n* Inadequately treated non-OSA sleep disorder(s).\n* Significant co-morbidities or prior surgeries that contra-indicate a surgical procedure or general anesthesia\n* Taking medications that in the opinion of the investigator may alter consciousness, the pattern of respiration, or sleep architecture\n* Participants on a GLP-1","21 Years",{"count":241,"type":22},30,[25],"The goal of this interventional study is to assess the safety and performance of the XII Medical Hypoglossal Nerve Stimulation (HGNS) System in people who have moderate to severe Obstructive Sleep Apnea (OSA).\n\nParticipation in this study involves being implanted with a Neurostimulator which provides electrical stimulation of the hypoglossal nerve (HGN). Participants will receive treatment at home during sleep, and participate in sleep studies to track and record the quality of the sleep. Participants will be monitored over the course of the study.",[29],[35,246],"HGNS",{"date":226,"type":48},{"date":249,"type":48},"2025-06-24",{"date":251,"type":22},"2029-06",{"name":253,"class":132},"XII Medical",6,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":262,"targetDuration":264,"studyType":265,"phases":4,"briefSummary":266,"conditions":267,"keywords":271,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100649505","osahs-screening-in-diverse-populations-100649505","NCT07736872","OSAHS Screening in Diverse Populations","Screening for Obstructive Sleep Apnea-hypopnea Syndrome - for Community Populations, Patients With Specific Diseases and Special Populations","Inclusion Criteria:\n\n* Sign the informed consent form before participating in the study\n* Complete independent behaviour and cognitive abilities\n* Ability to answer the questionnaire completely and accurately\n\nExclusion Criteria:\n\n* Incomplete answers to the scale\n* Patients with severe diseases and acute infections or those requiring long-term home oxygen therapy\n* Patients with severe mental and psychological disorders\n* Patients with severe organ failure\n* patients with a total sleep time \\\u003C240 min by PSG or PM",{"count":263,"type":22},100000,"2 Days","OBSERVATIONAL","The goal of this prospective observational study is to learn about the current prevalence of obstructive sleep apnea-hypopnea syndrome in community population, patients with specific diseases and special population from China. The main question it aims to answer is: (1) What are the prevalence and clinical characteristics of OSA in the community population, the specific disease population and the special population respectively? (2) How about the application value of each OSA screening questionnaire for different populations？Participants will all complete a screening questionnaire, and some will be selected by random sampling to complete either a polysomnography (PSG) or a portable sleep monitor (PM).",[29,268,269,270],"Snoring","Prevalence","Questionnaires and Surveys",[272,273,274,275,276,277,278],"osbtructive sleep apnea","snoring","prevalence","screening questionnaires","CNCQ-OSA","STOP-Bang","NoSAS","2026-07-26",{"date":226,"type":48},{"date":282,"type":48},"2024-09-01",{"date":284,"type":22},"2027-08-01",{"name":286,"class":55},"Kang Wu",2,{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":302,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":56},"100648411","identification-of-biomarkers-of-obstructive-sleep-apnea-100648411","NCT07723144","Identification of Biomarkers of Obstructive Sleep Apnea.","Identification of Biomarkers to Understand the Pathogenesis of Obstructive Sleep Apnea.","Inclusion Criteria:\n\n1. Participants with obstructive sleep apnea (OSA):\n\n   * Age 18 to 65 years.\n   * Moderate or severe obstructive sleep apnea confirmed by overnight polysomnography (apnea-hypopnea index \\[AHI\\] ≥15 events\u002Fhour).\n   * Willing and able to provide written informed consent.\n   * Willing to undergo repeated blood sampling and study assessments.\n   * Willing to use positive airway pressure (PAP) therapy and accept random assignment to immediate or delayed treatment.\n2. Control participants:\n\n   * Age 18 to 65 years.\n   * No obstructive sleep apnea (AHI \\\u003C5 events\u002Fhour on overnight polysomnography).\n   * Willing and able to provide written informed consent.\n   * Willing to undergo study assessments and blood sampling.\n\nExclusion Criteria:\n\n* Mild obstructive sleep apnea (AHI 5 to \\\u003C15 events\u002Fhour).\n* Central sleep apnea.\n* Previous treatment for obstructive sleep apnea within the previous 3 months.\n* Body mass index (BMI) ≥40 kg\u002Fm².\n* Severe cardiovascular disease.\n* Severe kidney disease or impaired renal function.\n* Significant liver disease.\n* Chronic inflammatory, autoimmune, or rheumatic disease.\n* Active cancer or other condition associated with systemic inflammation.\n* Chronic respiratory diseases, including asthma or chronic obstructive pulmonary disease.\n* Respiratory infection within 4 weeks before enrollment.\n* Major surgery or significant injury within the previous 3 months.\n* Chronic rhinosinusitis.\n* Current treatment with systemic corticosteroids, immunosuppressive drugs, cytotoxic drugs, chronic anti-inflammatory medications, or other medications that may influence inflammatory biomarkers.\n* Pregnancy or any condition that, in the opinion of the investigators, would make participation unsafe or interfere with interpretation of the study results.",{"count":98,"type":22},[25],"Obstructive sleep apnea (OSA) is a common sleep disorder associated with intermittent hypoxia, systemic inflammation, oxidative stress, and an increased risk of cardiovascular and metabolic diseases. Current diagnostic methods are effective but have limited availability and do not adequately predict disease burden or treatment response.\n\nThe purpose of this study is to identify and validate blood biomarkers that may improve the screening, diagnosis, risk stratification, and monitoring of adults with OSA. A total of 120 participants will undergo clinical evaluation and overnight polysomnography. Participants with moderate-to-severe OSA will be randomly assigned to either immediate or delayed positive airway pressure (PAP) therapy, while participants without OSA will serve as controls. Blood samples will be collected at predefined time points and analyzed for inflammatory, metabolic, oxidative stress, and other candidate biomarkers.\n\nThe study aims to determine which biomarkers are associated with OSA severity and how they change in response to PAP therapy. The results may contribute to the development of more accessible and personalized diagnostic and monitoring strategies for patients with OSA.",[36,29,299,300,301],"Obstructive Sleep Apnea (OSAS)","Obstructive Sleep Apnea (SAOS)","Obstructive Sleep Apnea (Moderate to Severe)",[104,35,303,106,304,116,305,306,307,308],"Positive airway pressure therapy","Blood biomarkers","Inflammation","Oxidative stress","Metabolomics","Precision medicine","2026-07-20",{"date":311,"type":48},"2026-07-23",{"date":313,"type":48},"2025-12-19",{"date":315,"type":22},"2029-06-19",{"name":317,"class":55},"Medical University of Bialystok",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":56},"100647890","effectiveness-of-audio-cues-to-achieve-positional-therapy-in-patients-with-positional-obstructive-sleep-apnea-100647890","NCT07714330","Effectiveness of Audio Cues to Achieve Positional Therapy in Patients With Positional Obstructive Sleep Apnea","Effectiveness of WhisperPT's Audio Cues to Achieve Positional Therapy in Patients With Positional Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Diagnosing sleep study identified a significant positional component to their obstructive sleep apnea (OSA) diagnosis as measured by at least a 50% reduction in Apnea-Hypopnea Index (AHI) while sleeping non-supine compared to supine\n* Diagnosing sleep study included at least 40% of the night recorded in supine and at least 20% of the night in non-supine position\n* Have an overall AHI \\> 10 (4% desaturation)\n* Diagnosing sleep study included a minimum of 5 hours total sleep time (TST)\n* Willing to abstain from use of any other treatments for sleep-disordered breathing beginning at least 3 days prior to at-home study testing and for the remaining duration of their study participation\n* Between ages 18-75\n* Must be able to refrain from alcohol use during nights of at-home study testing\n* Speaks and reads English sufficiently to understand the study informed consent, study instructions, and study materials\n* Signs study-specific informed consent form\n\nExclusion Criteria:\n\n-Active medical conditions that would prevent study participation as determined by the principal investigator, including: Inability to easily move from between back and side in both directions Inability to sleep in lateral or supine position due to injury or a medical condition OR inability to sleep in a non-elevated\u002F tilted bed\n\n* Requiring medications to sleep\n* Prior diagnosis of a significant other sleep disorder such as restless leg syndrome\u002Fperiodic limb movement disorder, primary central sleep apnea, pronounced insomnia, parasomnias, central disorder of hypersomnolence, etc\n* An active ear infection OR an ear infection within the past month OR a history of \\>3 ear infections per year\n* Unusual outer ear, including enlarged or extra small anatomy, that prevents device use\n* Significant hearing impairment or ear skin issues, including:\n\nParticipants with cochlear implants or those who will be affected by small magnets in the ear\n\n* Suffering from tinnitus\n* BMI \\>35\n* Current use of any illegal drugs.\n* Currently pregnant or currently lactating\n* Current enrollment in a clinical study of any other unapproved investigational drug or device.\n* Inability or unwillingness to comply with the study requirements.\n* Any other condition or laboratory value that could, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the participant.",{"count":241,"type":22},[25],"Patients with obstructive sleep apnea (OSA) often experience more frequent and severe breathing disturbances when sleeping in the supine (back-sleeping) position compared with non-supine positions. Positional therapy aims to reduce time spent sleeping in the supine position, but existing treatment options may be limited by comfort and effectiveness. This study evaluates the effectiveness and usability of WhisperPT, an investigational in-ear positional therapy device that delivers gentle audio cues during sleep to encourage participants to move from the supine to a non-supine sleeping position. The study will assess the device's ability to reduce the apnea-hypopnea index (AHI), decrease time spent sleeping supine, and evaluate participant comfort and ease of use.",[29,329],"Positional Obstructive Sleep Apnea",[329],"2026-07-17",{"date":127,"type":48},{"date":334,"type":48},"2026-06-25",{"date":336,"type":22},"2026-12-30",{"name":338,"class":132},"SleepDev, Inc",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":347,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100648209","clinical-trial-of-the-cryosa-system-for-the-treatment-of-obstructive-sleep-apnea-oasis-100648209","NCT07720219","Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea (OASIS)","Obstructive Sleep Apnea Severity Reduction by AdIpose CryolysiS","(OASIS)","Inclusion Criteria:\n\n1. Participant age is 22 years and older\n2. Participant has failed, is unable to use, unwilling to use or dissatisfied with Positive Airway Pressure (PAP) or mandibular advancement devices (MAD)\n3. Participant is diagnosed with Obstructive Sleep Apnea with an AHI ≥30 OR AHI ≥ 15 and BMI of ≥ 30 at enrollment (CA\u002FMA ≤ 25%)\n4. Participant is willing and capable of receiving the study procedure, completing all the questionnaires and returning for all follow-up evaluations and sleep studies\n5. Participant is willing and capable of providing informed consent\n\nExclusion Criteria:\n\n1. Participant is currently participating in other premarket investigational studies unless approved by Sponsor in writing\n2. Any reason for which, in the judgment of the investigator, the participant is considered to be a poor study candidate, which may include, but is not limited to: any uncontrolled neurological, medical, social, or psychological problems that could complicate the required procedures and evaluations of the study (e.g. uncontrolled Type 1 or 2 diabetes with neuropathy, debilitating acute or chronic cardiac, lung, liver, kidney, central nervous system or psychiatric disease)\n3. Participant has a BMI \\> 40 kg\u002Fm2 at enrollment\n4. Women who are pregnant or of childbearing potential (WOCBP defined as fertile following menarche and until becoming post-menopausal unless permanently sterile) who are unwilling to practice an appropriate method of contraception from screening through 6-month follow-up.\n\n   Concomitant Medication Exclusions\n5. Participant is actively taking ACEs\u002FARBs for hypertension AND is either of black race, of female gender, or \\>65 years of age\n6. Participant is actively undergoing immunotherapy (Allergy shots), and unwilling to wash out of allergy shots at least 2 weeks prior to study procedure\n7. Participant is taking any of the following medications that, in the opinion of the investigator, could affect study endpoints: AD109, benzodiazepines, Z-drugs (zolpidem and eszopiclone), opiates, antipsychotics (neuroleptics), phenothiazines, and prescription stimulants (including Sunosi, Provigil, and Nuvigil)\n\n   Significant Airway Risk Factors\n8. Participants with severe uncontrolled asthma\n9. Participants with a history of angioedema\n10. Participants with hereditary angioedema (confirmed with a Complement Component C4 blood test \\\u003C13mg\u002FdL)\n11. Participant has uncontrolled autoimmune disorders including active thyroid disease, lupus, multiple myeloma, and chronic lymphocytic leukemia that could lead to acquired angioedema\n12. Participant has a history or presence of cold urticaria at the time of screening\n13. Participant has a history of cryoglobulinemia or Paradoxical Adipose Hyperplasia (PAH)\n14. Participant has a history of allergy to glycerin History of Oral\u002FAirway Comorbidities\u002FInterventions\n15. Participant has a prior airway interventions that alter or excise the tissue of the soft palate or the tongue base\n16. Participant has any airway intervention within 12 weeks of scheduled procedure performed to alter or excise the soft tissue of the airway or larynx\n17. Participant has an active, implanted, nerve stimulator for the treatment of OSA\n18. Participant has oral cancer or non-healing oral wounds\n19. Participant has a history of radiation therapy to neck or upper respiratory tract\n20. Participant has other severe sleep disorders that, in the opinion of the investigator, confound functional assessments of sleepiness such as narcolepsy with cataplexy, severe insomnia\u002Finsomnia secondary to chronic pain, PTSD\n\n    Major Anatomical Exclusions\n21. Participant has severe maxillary mandibular insufficiency or obvious severe fixed upper airway obstructions (tumors, polyps, nasal obstruction) that, in the opinion of the investigator, is thought to be the primary cause of OSA\n22. Participant has obstructions identified at the tonsils (palatine tonsils size 3+ or 4+)\n23. Participant has lingual tonsils size 4+\n24. Participant has Friedman tongue position IV\n25. Participant has a mandibular intermolar width \\\u003C 32mm\n26. Participant has trismus as defined by a maximal inter-incisal opening of \\\u003C 35mm\n\n    Significant Comorbidities that Contraindicate Surgery or General Anesthesia\n27. Participant has resistant hypertension, defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses\n28. Diagnosis of any moderate to severe congestive obstructive pulmonary disease (COPD)\n29. Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism).\n30. Uncontrolled Diabetes (including Diabetes Mellitus \\[DM\\] or Insulin Dependent Diabetes Mellitus \\[IDDM\\]) with HbA1c \\>9 at time of screening.\n31. Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (\\\u003C 12 months) myocardial infarction or severe cardiac arrhythmias\n32. Participants with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months\n33. Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months\n34. Participant has contraindication to general anesthesia or, in the opinion of the Investigator, would not be able to tolerate the procedure, including intubation during the procedure\n\n    Lifestyle considerations\n35. Participant is a current smoker or nicotine vaper (\\>1 pack\u002Fday or equivalent)\n36. Participant conducts work or regular activities requiring vigilance (e.g., commercial driver, heavy machine operator, shift worker, etc.) that does not accommodate untreated OSA.\n37. Participant has sleep hygiene behavior that is likely to interfere with measurement outcomes during PSG\n38. Participant exhibits ongoing misuse of alcohol or recreational drugs that would impact either the results of or the participation in a sleep study","22 Years",{"count":349,"type":22},130,[25],"The objective of this study is to evaluate the safety and effectiveness of the Cryosa System when used as intended to perform the Cryosa Procedure.",[29,353,35],"Sleep Apnea - Obstructive",[355,356,35,357,36],"OASIS","Crysoa","Cryotherapy","2026-07-16",{"date":360,"type":48},"2026-07-22",{"date":362,"type":22},"2026-10",{"date":364,"type":22},"2029-11",{"name":366,"class":132},"Cryosa, Inc.",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":382,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":56},"100647719","implantable-hypoglossal-nerve-stimulation-for-obstructive-sleep-apnea-100647719","NCT07711678","Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea","A Pilot Study of Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea","Inclusion Criteria\n\n1. Age 18 years or older, regardless of sex.\n2. Moderate-to-severe obstructive sleep apnea confirmed by polysomnography, with an apnea-hypopnea index of 15 to 100 events per hour.\n3. Prior failure of, intolerance to, or unwillingness to continue positive airway pressure therapy.\n4. Body mass index ≤40 kg\u002Fm².\n5. Able to communicate with the investigator, understand the study requirements, and provide written informed consent.\n6. Willing and able to comply with study procedures and complete postoperative follow-up visits.\n\nExclusion Criteria\n\n1. Central and mixed apnea and hypopnea events account for more than 25% of the total apnea-hypopnea index.\n2. Presence of obvious fixed upper airway obstruction or obstructive upper airway lesions, including but not limited to tumors or masses, polyps, scar stenosis, or severe nasal septal deviation involving the nasal cavity, nasopharynx, oropharynx, hypopharynx, or larynx, which, in the investigator's judgment, may affect device implantation, treatment effect, or evaluation of the primary effectiveness endpoint.\n3. Abnormal hypoglossal nerve function; neurological or neuromuscular disease that may affect upper airway neuromuscular control or tongue movement; or clinically significant dysphagia.\n4. Severe cardiopulmonary disease, including but not limited to chronic obstructive pulmonary disease, severe asthma, chronic respiratory failure, myocardial infarction, or severe arrhythmia.\n5. Any disease or condition that precludes general anesthesia or may interfere with implantation of the hypoglossal nerve stimulation system.\n6. Pregnant or lactating women, or women planning pregnancy during the study period.\n7. Any condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.\n8. Participation in another clinical trial within 4 weeks before signing informed consent.\n9. Presence of an implanted active medical device that may interact with the investigational hypoglossal nerve stimulation system, affect treatment effectiveness, or compromise participant safety.\n10. Unable or unwilling to discontinue other obstructive sleep apnea-related treatments during the study, except for the investigational hypoglossal nerve stimulation system manufactured by Beijing PINS Medical Co., Ltd.",{"count":375,"type":22},10,[25],"The objective of this study is to evaluate the safety and preliminary effectiveness of an implantable hypoglossal nerve stimulation system for moderate-to-severe obstructive sleep apnea (OSA).",[29,379,380,381],"Syndrome, Obstructive Sleep Apnea","Respiration Disorders","Sleep Apnea Syndrome, Obstructive",[383],"Hypoglossal nerve stimulation","2026-07-14",{"date":331,"type":48},{"date":387,"type":22},"2026-07-15",{"date":389,"type":22},"2027-02-28",{"name":391,"class":132},"Beijing Pins Medical Co., Ltd",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":265,"phases":4,"briefSummary":401,"conditions":402,"keywords":405,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":419,"locationsCount":4},"100646284","empirical-cpap-therapy-for-suspected-obstructive-sleep-apnea-in-a-resource-limited-setting-100646284","NCT07693101","Empirical CPAP Therapy for Suspected Obstructive Sleep Apnea in a Resource-Limited Setting","Clinical Outcomes of Empirical CPAP Therapy in Suspected Obstructive Sleep Apnea Patients in a Resource-Limited Setting: Observational Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years.\n* Patients presenting with symptoms suggestive of OSA, including one or more of the following: excessive daytime sleepiness, habitual snoring, witnessed apnea during sleep, non-restorative sleep, or morning headache.\n* High clinical probability of OSA defined by: STOP-BANG score ≥5 or STOP-BANG score 3-4 with ESS ≥10.\n* Patients awaiting diagnostic PSG due to delayed access to sleep laboratory services.\n* Patients with OSAS and COPD overlap.\n* Obesity hypoventilation syndrome requiring automated CPAP.\n* Ability and willingness to use CPAP and provide informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Pregnancy.\n* Previous PSG-confirmed OSA with prescribed CPAP settings.\n* Predominant central sleep apnea.\n* Cheyne-Stokes respiration.\n* Neuromuscular disorders affecting respiration.\n* Severe psychiatric illness impairing adherence.\n* Inability to provide informed consent.\n* Severe unstable cardiopulmonary disease requiring urgent respiratory support, including: acute heart failure, acute coronary syndrome, acute respiratory failure, or severe COPD with chronic hypercapnic respiratory failure requiring NIV rather than CPAP.\n* Obesity hypoventilation syndrome requiring bilevel PAP (BiPAP) instead of CPAP.",{"count":400,"type":22},80,"Obstructive sleep apnea (OSA) is a condition where a person's airway repeatedly collapses during sleep, causing them to stop breathing briefly and disrupting their rest. The standard way to diagnose OSA is a formal overnight sleep study called polysomnography (PSG). However, in resource-limited settings, sleep study centers are scarce, which can lead to months of waiting before a patient can be diagnosed and treated. Delaying treatment can negatively affect a patient's quality of life and increase their risk for other health issues.\n\nThe purpose of this observational study is to evaluate the clinical benefits of starting continuous positive airway pressure (CPAP) therapy early for patients who are highly suspected to have OSA, while they wait for their formal sleep study.\n\nResearchers will enroll adult patients who have symptoms of OSA (such as loud snoring, witnessed breathing pauses, and severe daytime sleepiness) and a high clinical probability of having the condition. Instead of waiting for the official sleep study to begin treatment, these participants will be provided with an Auto-CPAP machine set to a practical pressure range.\n\nThe main goals of the study are to evaluate:\n\n* If this early, empirical Auto-CPAP treatment improves patients' daytime sleepiness and overall quality of life, which will be measured using specialized questionnaires.\n* How accurately the temporary Auto-CPAP machine's pressure settings match the final, optimal pressure settings that will eventually be determined by the formal sleep study.",[29,403,404],"Suspected Obstructive Sleep Apnea","Sleep Apnea Syndromes",[36,35,406,106,407,408,409,116,410,411,412],"Continuous Positive Airway Pressure","Auto-CPAP","Empirical Therapy","Empirical CPAP","Resource-Limited Setting","STOP-BANG","Epworth Sleepiness Scale","2026-07-03",{"date":415,"type":48},"2026-07-09",{"date":177,"type":22},{"date":418,"type":22},"2027-09",{"name":420,"class":55},"Assiut University",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":4},"100646743","level-3-validation-study-100646743","NCT07688603","Level 3 Validation Study","Comparison of Home Level 3 Polysomnography to In-Laboratory Polysomnography","Inclusion Criteria:\n\n* Referred for a diagnostic sleep study\n\nExclusion Criteria:\n\n* under the age of 18\n* significant cardiopulmonary disease, neuromuscular disease or stroke\n* other significant sleep disorders\n* use of opiate medications",{"count":400,"type":22},[25],"This study will compare the output of a new Level 3 polysomnography system against in-laboratory polysomnography.",[29],"2026-07-02",{"date":434,"type":48},"2026-07-07",{"date":436,"type":22},"2026-06",{"date":438,"type":22},"2026-11",{"name":440,"class":55},"Windsor Sleep Disorders Clinic",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":460,"leadSponsor":462,"locationsCount":56},"100644895","mandibular-advancement-device-mad-and-continuous-positive-airway-pressure-cpap-for-treatment-of-adult-patients-diagnosed-with-moderate-obstructive-sleep-apnea-100644895","NCT07677332","Mandibular Advancement Device (MAD) and Continuous Positive Airway Pressure (CPAP) for Treatment of Adult Patients Diagnosed With Moderate Obstructive Sleep Apnea","Mandibular Advancement Device (MAD) and Continuous Positive Airway Pressure (CPAP) for Treatment of Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Objectively diagnosed with moderate OSA (AHI 15-29)\n* \\>\u002F= 18 years\n* BMI \\\u003C\u002F= 35 and neck circumference \\\u003C44cm\n* Fully sanitised at their own dentist (no periodontitis or caries requiring treatment. Periodontal bone loss \\\u003C50%)\n* \\>\u002F= 20 teeth.\n* Evenly distributed occlusal contacts\n\nExclusion Criteria:\n\n* Known craniofacial anomalies\n* General inflammatory joint diseases\n* Maximal protrusion of the mandible \\\u003C 6 mm\n* Severe deep bite\n* Anterior open bite\n* Severe attrition\n* Severe bruxism and involuntary mandibular movements\n* Conditions demanding treatment such as temporomandibular disorders (TMD)\n* Chronically pronounced nasal stenosis\n* Hypertrophic tonsils (tonsil size 3-4)\n* Prior blood clot in the brain or in the heart\n* Heart arrythmias\n* Other severe systemic diseases\n* Epilepsia\n* Allergies towards peanuts, soy or egg\n* Consumption of morphine or other sedatives which cannot be paused\n* Pregnant or breast-feeding women",{"count":449,"type":22},70,[25],"Obstructive sleep apnea (OSA) is a frequent illness related to sleep and breathing with many symptoms and complications. The primary choices of treatment are continuous positive airway pressure (CPAP) and removable appliance for protruding the mandible when sleeping (MAD). Treatment with CPAP is superior to treatment with MAD but many patients don't tolerate CPAP why they seek treatment with MAD. In Denmark, treatment with MAD is not free of charge unlike treatment with CPAP and MAD is therefore not offered systematically to the patients. The same applies to adjustment, control and effect of the MAD treatment. MAD treatment has a positive effect on OSA in general but the effect varies due to differences in selection of patients and lack of specifying who performs and evaluates MAD treatment, the effect on sleep and possible side effects in muscles and the temporomandibular joint as well as the occlusion during treatment. It is therefore of great importance to investigate the effect of MAD treatment as well as short- and long-term side effects. The aim is therefore to compare the treatment effect of MAD and CPAP and how significant the investigation of the airways and the face is for the treatment effect and possible side effects. The project is a 4-year investigation and 70 adult patients diagnosed with moderate OSA are included. The results from the investigation will be of great importance for the choice of treatment and prognosis for the individual patient and socio-economic since the treatment of OSA could be tailored the individual patient and the treatment effect optimised.",[29],[104,35,454,106,455],"MAD","Orthodontics","2026-06-29",{"date":458,"type":48},"2026-06-30",{"date":177,"type":22},{"date":461,"type":22},"2029-08",{"name":463,"class":55},"University of Copenhagen",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":471,"maxAge":96,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":481,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":56},"100642932","exercise-interventions-in-obstructive-sleep-apnea-syndrome-100642932","NCT07634029","Exercise Interventions in Obstructive Sleep Apnea Syndrome","The Effect of Exercise Snacks and Aerobic Exercise on Circadian Rhythm and Functional Capacity in Individuals With Obstructive Sleep Apnea Syndrome","Inclusion Criteria:\n\n* Individuals diagnosed with OSAHS (AHI ≥ 15) confirmed by polysomnography, with moderate or severe disease, who have been receiving CPAP therapy for at least 3 months.\n* Adults aged 30-65 years.\n* No participation in any regular exercise program within the last 6 months.\n\nExclusion Criteria:\n\n* Individuals with OSAHS and a body mass index (BMI) \\> 35 kg\u002Fm²\n* Severe chronic pulmonary disease\n* Neurological or musculoskeletal disorders that prevent exercise\n* Unstable cardiovascular conditions\n* Unstable metabolic conditions\n* Severe psychiatric disorders such as bipolar disorder or schizophrenia\n* Pregnancy or breastfeeding\n* Individuals working night shifts or with schedules that may cause jet lag\n* Use of steroid or hormone therapy\n* Use of melatonin or sleep-regulating medications within the last 3 months\n* Presence of acute infection or inflammation","30 Years",{"count":473,"type":22},39,[25],"Obstructive Sleep Apnea Syndrome (OSA) is a condition characterized by repeated pauses or reductions in breathing during sleep, which can negatively affect sleep quality, daytime functioning, and physical capacity. Although regular exercise is known to have beneficial effects in OSA, the effects of different exercise approaches on circadian rhythm and functional capacity have not been sufficiently investigated.The primary aim of this study is to compare the effects of exercise snacking and aerobic exercise on circadian rhythm and functional capacity in individuals with OSA, in comparison with a control group. The secondary aim is to evaluate the effects of these exercise interventions on peripheral muscle strength, fatigue level, body composition, quality of life, and physical activity level.Participants will be randomly assigned to three groups: an aerobic exercise group, an exercise snacking group, and a control group. While the exercise groups will follow their respective intervention programs, the control group will continue their routine treatment.This study aims to answer whether exercise snacking, which consists of short bouts of exercise distributed throughout the day, may be an alternative or complementary approach to traditional aerobic exercise in individuals with OSA. In addition, this study aims to be the first randomized controlled trial evaluating the effects of exercise snacking on circadian rhythm and functional capacity in individuals with OSA.",[29,477,478,479,480],"Exercise Snacks","Physical Activity","Circadian Rhythm","Sleep",[36,482,483,484],"exercise training","circadian rhythm","exercise snacks","2026-06-03",{"date":487,"type":48},"2026-06-08",{"date":82,"type":22},{"date":490,"type":22},"2028-02",{"name":492,"class":55},"Istanbul University - Cerrahpasa",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":17,"sex":18,"minAge":499,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":265,"phases":4,"briefSummary":502,"conditions":503,"keywords":506,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":518,"locationsCount":56},"100638521","early-dental-risk-screening-for-pediatric-sleep-disordered-breathing-100638521","NCT07581938","Early Dental Risk Screening for Pediatric Sleep-Disordered Breathing","Inclusion Criteria:\n\n* Ages 8-13 years old\n* American Society of Anesthesiologists Class I or II\n* Ability to read and understand the English or Spanish language\n* Ability to assent, with parent\u002Flegal guardian able to provide informed consent\n* Access to a smartphone capable of supporting the wearable monitoring application\n\nExclusion Criteria:\n\n* Diagnosis of a craniofacial syndrome or condition known to significantly alter craniofacial morphology\n* Prior diagnosis of sleep disordered breathing and\u002For obstructive sleep apnea\n* History of adenotonsillectomy\n* Prior or current orthodontic treatment\n* Prior orthognathic surgery","8 Years","13 Years",{"count":143,"type":22},"This is a prospective, cross-sectional observational study designed to evaluate the Pediatric Sleep Questionnaire (PSQ) as a screening tool for sleep-disordered breathing (SDB) risk in a pediatric dental setting. Children aged 8-13 years will be classified as low- or high-risk for SDB based on PSQ scores and compared using physiologic sleep parameters obtained from a wearable, FDA-cleared home sleep monitoring device, alongside psychosocial assessments and craniofacial measurements derived from lateral cephalometric radiographs. Findings will inform the feasibility and accuracy of incorporating validated SDB screening into routine pediatric dental care.",[504,505,29],"Early Risk Screening for Sleep Disordered Breathing in a Dental Setting","Sleep Disordered Breathing (SDB)",[507,508,29,505,509,510,511,39,512],"Pediatric Sleep Questionnaire","Apnea","Pediatric Dentistry","At-Home Sleep Study","Pediatric","Lateral Ceph","2026-06-02",{"date":515,"type":48},"2026-06-04",{"date":436,"type":22},{"date":129,"type":22},{"name":519,"class":55},"University of North Carolina, Chapel Hill",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":265,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":56},"100638036","the-impact-of-volume-overload-on-obstructive-sleep-apnea-in-patients-with-congestive-heart-failure-100638036","NCT07601724","The Impact of Volume Overload on Obstructive Sleep Apnea in Patients With Congestive Heart Failure","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Hospitalized with decompensated heart failure and clinical evidence of fluid overload\n* Diagnosis of heart failure (reduced or preserved ejection fraction)\n* Clinically indicated for diuretic therapy\n* Able to undergo sleep apnea assessment using the WatchPAT device\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Known central sleep apnea as the predominant sleep-disordered breathing type\n* Current treatment with continuous positive airway pressure (CPAP)\n* Acute respiratory failure requiring mechanical ventilation\n* Conditions preventing proper use of the WatchPAT device (e.g., severe hand or finger injury)\n* Hemodynamic instability precluding participation\n* Pregnancy",{"count":527,"type":22},50,"The goal of this observational study is to learn how removing extra fluid from the body (diuresis) affects sleep apnea in adults hospitalized with heart failure.\n\nThe main questions it aims to answer are:\n\nDoes sleep apnea severity improve after fluid removal? Is the improvement in sleep apnea related to the amount of fluid removed? Do changes in neck size reflect changes in sleep apnea severity?\n\nParticipants admitted to the hospital with heart failure and fluid overload will take part in this study.\n\nParticipants will:\n\nUse a wearable sleep monitoring device (WatchPAT) on the first night of hospitalization Use the device again after fluid removal, when the treating cardiologist determines that the patient is no longer fluid overloaded Have their neck circumference measured before and after fluid removal Have their weight and fluid balance recorded during hospitalization Have routine blood tests and clinical assessments as part of standard care\n\nResearchers will compare each participant's results before and after fluid removal to see if sleep apnea improves and whether these changes are linked to fluid removal and changes in neck circumference.",[530,29],"Heart Failure","2026-05-19",{"date":533,"type":48},"2026-05-22",{"date":535,"type":48},"2026-01-01",{"date":537,"type":22},"2027-06",{"name":539,"class":55},"Itshak Amsalem",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":265,"phases":4,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":56},"100587593","data-collection-study-to-review-novel-methods-for-diagnosing-obstructive-sleep-apnea-100587593","NCT06930404","Data Collection Study to Review Novel Methods for Diagnosing Obstructive Sleep Apnea","Innovation and Growth Network for Insightful Trends and Evaluation - Data Collection Study","Ignite","Inclusion Criteria:\n\nAdults aged \\>= 18 Ability to read and comprehend English\n\nExclusion Criteria:\n\n* Previous diagnosis of OSA\n* Respiratory diseases (such COPD, lung cancer, fibrosis of the lungs, lung injury)\n* Subjects who are or may be pregnant, breastfeeding or within 6 weeks postpartum (which may impact HRV temporarily)\n* Subjects with a pacemaker",{"count":549,"type":22},800,"This study will collect data on a range of signals such as facial scans, videos (including speaking, blinking and swallowing) and heart rate variability to assess whether any of these measures are useful for diagnosing obstructive sleep apnea",[29],[553,554],"diagnosis","screening","2026-05-17",{"date":531,"type":48},{"date":558,"type":48},"2025-09-15",{"date":560,"type":22},"2027-02-15",{"name":562,"class":132},"ResMed",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":571,"maxAge":19,"enrollmentInfo":572,"targetDuration":4,"studyType":23,"phases":574,"briefSummary":575,"conditions":576,"keywords":577,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":56},"100638343","cpap-vs-high-flow-nasal-cannula-for-treating-sleep-apnea-in-children-100638343","NCT07600333","CPAP vs High-Flow Nasal Cannula for Treating Sleep Apnea in Children","Continuous Positive Airway Pressure vs High Flow Nasal Cannula for the Treatment of OSA in Children","CHOSA","Inclusion Criteria:\n\n* Aged 2 to 18 years\n* Diagnosed with moderate to severe obstructive sleep apnea, defined as an obstructive apnea-hypopnea index (OAHI) ≥5 events\u002Fhour, confirmed by an in-laboratory polysomnography within the previous 6 months\n* Deemed to require Continuous Positive Airway Pressure (CPAP) therapy as part of usual clinical care\n* Ability of the participant and\u002For parent or legal guardian to provide informed consent (and assent when applicable)\n\nExclusion Criteria:\n\n* Predominant or pathological central sleep apnea (central apnea-hypopnea index ≥5 events\u002Fhour)\n* Chronic respiratory failure or medical conditions requiring ventilatory support with a set respiratory rate (e.g., neuromuscular disease requiring bilevel ventilation with a backup rate)\n* Hypoventilation requiring non-invasive ventilation with a set respiratory rate\n* History of pneumothorax or pneumomediastinum\n* Uncontrolled gastroesophageal reflux and\u002For recurrent vomiting\n* Uncontrolled oral secretions\n* Prior use of CPAP or High-Flow Nasal Cannula therapy for treatment of obstructive sleep apnea within the previous 12 months","2 Years",{"count":573,"type":22},258,[25],"This study is looking at two different treatments for obstructive sleep apnea (OSA) in children. OSA is a sleep condition where breathing repeatedly stops and starts during sleep, which can affect a child's health, behavior, learning, and quality of life.\n\nChildren with moderate-to-severe OSA who cannot be treated with surgery are often prescribed Continuous Positive Airway Pressure (CPAP). CPAP uses a mask worn during sleep to deliver pressurized air and keep the airway open. Although CPAP is effective, many children have difficulty using it regularly because it can feel uncomfortable or hard to tolerate.\n\nThis study compares CPAP with another treatment called High-Flow Nasal Cannula (HFNC). HFNC delivers warm, humidified air through soft nasal prongs and may be more comfortable and easier for children to use while still helping keep the airway open during sleep.\n\nChildren aged 2 to 18 years with moderate-to-severe OSA will be randomly assigned to use either CPAP or HFNC at home during sleep for 3 months. The study will measure how much each treatment is used, how well it improves sleep-related symptoms and quality of life, how comfortable it is for children, and how it affects caregivers.\n\nThe goal of this study is to find out whether HFNC is a comfortable and effective alternative to CPAP for treating obstructive sleep apnea in children.",[29],[578,579,580,581,582,106,583,584,585,586,587,588,589],"obstructive sleep apnea","pediatric obstructive sleep apnea","children","adolescents","continuous positive airway pressure","High Flow nasal cannula","HFNC","Sleep-disordered breathing","adherence","quality of life","home sleep therapy","randomized controlled trial","2026-05-14",{"date":592,"type":48},"2026-05-20",{"date":594,"type":22},"2026-06-01",{"date":596,"type":22},"2031-12",{"name":598,"class":55},"The Hospital for Sick Children",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":606,"maxAge":607,"enrollmentInfo":608,"targetDuration":4,"studyType":23,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":56},"100618527","effect-of-adenotonsillectomy-on-spinal-curve-magnitude-in-children-with-sleep-disordered-breathing-100618527","NCT07332780","Effect of Adenotonsillectomy on Spinal Curve Magnitude in Children With Sleep-Disordered Breathing","A Randomized Controlled Study of Adenotonsillectomy on Spinal Curve Magnitude in Children With Mild Sleep-Disordered Breathing","Inclusion Criteria:\n\n1. Age between 6 and 15 years.\n2. Diagnosed with mild SDB, defined as: Obstructive Apnea-Hypopnea Index (OAHI) ≤5 events\u002Fhour on a laboratory-based PSG performed within the past 6 months, AND parental report of habitual obstructive breathing symptoms (e.g., snoring, mouth-breathing, witnessed apneas) occurring \\>3 nights per week on average.\n3. Tonsillar hypertrophy grade ≥2 (on a scale of 0-4) and deemed an appropriate candidate for AT upon ENT evaluation (i.e., no absolute contraindications such as submucous cleft palate).\n4. Has undergone radiographic screening for idiopathic scoliosis at the first clinic visit.\n5. Skeletally immature (Risser sign 0-3) with spinal Cobb angle \\\u003C 40 degrees.\n6. Informed consent\u002Fassent provided by the participant and guardian.\n\nExclusion Criteria:\n\n1. Unwillingness or inability to comply with study procedures.\n2. Plans to relocate outside the study area within 24 months.\n3. Previous tonsillectomy or adenoidectomy.\n4. Recurrent tonsillitis meeting guideline criteria for immediate AT.\n5. Severe OSA (OAHI \\>10 or as per clinician judgment) or significant hypoxemia requiring immediate CPAP therapy.\n6. Severe chronic conditions that could confound outcomes, including but not limited to:\n\n   * Known syndromic, neuromuscular, or congenital musculoskeletal causes of scoliosis.\n   * History of spine surgery or significant spinal injury.\n   * Spinal tumor.\n   * Leg length discrepancy \\>20 mm.\n   * Severe cardiopulmonary disease (e.g., cystic fibrosis, congenital heart disease).\n   * Significant cardiac arrhythmia noted on PSG.\n   * Bleeding disorders, Sickle Cell Disease.\n   * Uncontrolled diabetes, narcolepsy, or asthma.\n   * Known genetic, craniofacial, neurological, or psychiatric conditions likely to affect the airway or study participation.\n   * Severe obesity (BMI z-score ≥ 3).","6 Years","15 Years",{"count":609,"type":22},160,[25],"This study aims to determine the effect of adenotonsillectomy (AT) surgery on the progression of spinal curvature in children with mild sleep-disordered breathing (SDB) and concurrent scoliosis, as well as its potential role in preventing the de novo development of scoliosis in children with SDB.",[613,614,29],"Sleep-disordered Breathing (SDB)","Idiopathic Scoliosis",{"date":616,"type":48},"2026-05-15",{"date":618,"type":48},"2025-07-11",{"date":620,"type":22},"2028-07-31",{"name":622,"class":55},"Second Affiliated Hospital of Wenzhou Medical University",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":23,"phases":631,"briefSummary":632,"conditions":633,"keywords":639,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":650,"locationsCount":56},"100600934","ioa-preventing-occlusal-changes-with-mad-use-100600934","NCT07103941","IOA Preventing Occlusal Changes With MAD Use","Effectiveness of Interocclusal Aligner (IOA) on Preventing Occlusal Changes in Patients Treated With a Mandibular Advancement Device (MAD): A Preliminary Study","Inclusion Criteria:\n\n* adult participants (≥18 years)\n* diagnosed with SRBD and prescribed Mandibular Advancement Device (MAD) therapy\n* Participants will include patients with well restored natural dentition with all posterior teeth, excluding third molars, one missing premolar secondary to orthodontic treatment.\n\nExclusion Criteria:\n\n* pervious orthognathic surgery\n* anterior cross bite\n* posterior cross bite\n* existing open bite or implant supported restorations\n* tooth mobility\n* significant dental caries or periodontitis\n* severe bruxism\n* planned upcoming dental work including caps, crowns, implants, or braces\n* inadequate mandibular protrusion\n* severe micrognathia\n* large tori\n* significant claustrophobia\n* significant nasal obstruction\n* large oropharyngeal masses or large tonsils",{"count":241,"type":22},[25],"This study is evaluating two standard-of-care strategies used to prevent bite changes (occlusal changes) in patients treated with a Mandibular Advancement Device (MAD) for sleep-related breathing disorders such as obstructive sleep apnea (OSA). While MAD therapy is effective, it can lead to changes in how the teeth fit together, including the development of a posterior open bite.\n\nParticipants in this study will be randomly assigned to one of two standard-of-care approaches: using an interocclusal aligner each morning after removing the MAD, or performing daily jaw exercises. Both methods aim to reduce the risk of occlusal changes.\n\nThe study will follow participants over a 3-month period and includes dental evaluations, 3D oral scans, and short daily surveys. Findings from this research may help guide best practices for preserving occlusion during MAD therapy.",[634,268,29,635,636,637,638],"Sleep Related Breathing Disorder","Open Bite","Occlusal Changes","Tooth Migration","Posterior Open Bite",[640,641,638,636,642,643,644,36],"Interocclusal Aligner","Mandibular advancement Device","Dental Changes","Protrusion","Sleep Appliance",{"date":646,"type":48},"2026-05-18",{"date":648,"type":48},"2025-11-17",{"date":336,"type":22},{"name":651,"class":55},"Isabel Moreno Hay",{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":662,"conditions":663,"keywords":667,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":679},"100616588","high-flow-nasal-cannula-for-preventing-hypoxia-during-sedated-endoscopy-in-high-risk-obstructive-sleep-apnea-patients-100616588","NCT07307560","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients: A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* STOP-Bang score ≥5.\n* Scheduled for sedated gastrointestinal endoscopy (gastroscopy, colonoscopy, or combined gastroscopy + colonoscopy).\n* The estimated duration of the procedure does not exceed 45 minutes.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Coagulation disorders or bleeding tendency (e.g., oral\u002Fnasal bleeding risk, mucosal injury, space-occupying obstructions).\n* Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature \\>37.5°C).\n* Chronic obstructive pulmonary disease or other acute\u002Fchronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air.\n* Severe organ dysfunction, including: Cardiac insufficiency (\\\u003C4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV.\n* Confirmed pregnancy or current breastfeeding.\n* Known allergy to sedatives (e.g., propofol) or medical adhesives.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator",{"count":660,"type":22},600,[25],"Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests that High-Flow Nasal Cannula (HFNC) may lower the incidence of hypoxemia, evidence remains limited and inconsistent in studies specifically targeting high-risk OSA populations. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxia during sedated gastrointestinal endoscopy in patients identified as high-risk for OSA.",[664,665,666,29],"Hypoxia","Esophageal Cancer","Gastric Cancer (Diagnosis)",[668,664,29,669],"Sedation","Gastrointestinal Endoscopy","2026-05-01",{"date":672,"type":48},"2026-05-04",{"date":674,"type":48},"2025-12-21",{"date":676,"type":22},"2026-12-01",{"name":678,"class":55},"Zhejiang University",3,{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":688,"targetDuration":4,"studyType":23,"phases":689,"briefSummary":690,"conditions":691,"keywords":692,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":696,"completionDateStruct":697,"leadSponsor":699,"locationsCount":4},"100636332","phase-4-informing-patients-with-oximetry-data-to-improve-mad-engagement-100636332","NCT07564310","INFORMing Patients With Oximetry Data to Improve MAD Engagement","INFORMing Patients With Oximetry Data to Improve Mandibular Advancment Device (MAD) Engagement","INFORM","Inclusion Criteria:\n\n* Participants willing to give written informed consent; Participants who can read and comprehend English; ≥ 18 years of age; Participants who have mild-to-moderate OSA, or severe OSA where CPAP has failed, is not tolerated, or is refused; Participants who can participate in the study for up to 4 weeks; Participants who own and can use a smartphone that is compatible with the study app; Participants who have the cognitive ability to follow the study instructions and procedures; Participants who have undergone a panoramic X-ray and are deemed suitable for MRD use\n\nExclusion Criteria:\n\n* Participants who are pregnant or may be pregnant; Participants who have a major psychiatric disorder that, in the investigator's opinion, could interfere with participation; Participants who have severe insomnia, for example usually sleeping less than about four hours per night; Participants believed to be unsuitable for the study for safety or other medical reasons by the investigator; Participants who are currently enrolled in another medical clinical study; Participants who have central sleep apnoea; Participants who have severe respiratory disorders other than OSA; Participants who have dental contraindications to using an oral appliance, such as loose teeth or advanced periodontal (gum) disease; Participants who have a completely edentulous lower arch (no lower teeth) unless a complete denture that is mechanically retained (for example, by implants) is present; Participants who have a completely edentulous upper arch (no upper teeth) unless a complete upper denture is present; Participants who have short teeth and\u002For insufficient undercuts to retain the device securely",{"count":98,"type":22},[68],"Obstructive sleep apnea (OSA) is common and associated with impaired daytime functioning, reduced quality of life and increased cardiovascular, metabolic and perioperative risk.\n\nMandibular advancement devices (MADs) are a guideline-supported, non-invasive alternative to CPAP for patients with mild to moderate OSA and for those with severe OSA who refuse or cannot tolerate CPAP.\n\nMAD therapy relies heavily on patient engagement and sustained use over time. However, in usual care, patients typically have limited access to objective information about their treatment response. Titration is often based on intermittent assessments and subjective symptom reporting, with little real-time feedback to patients on treatment effectiveness.\n\nThis lack of visibility may limit patient understanding of their condition, reduce engagement with therapy, and delay optimisation of treatment.\n\nAdvances in nocturnal oximetry now enable multi-night, home-based assessment of oxygen desaturation and related metrics. The myNarval CC solution provides patients, alongside clinicians, with access to objective oximetry data during MAD therapy. By increasing patient awareness of treatment response, this approach has the potential to enhance engagement, support adherence, and improve the overall treatment experience.\n\nThe purpose of this study is to evaluate whether access to oximetry data through the myNarval CC solution improves patient-reported experience measures (PREMs) compared with standard care in patients treated with MADs for OSA.",[29],[693],"mandibular advancement device MAD","2026-04-26",{"date":672,"type":48},{"date":594,"type":22},{"date":698,"type":22},"2027-05-01",{"name":562,"class":132}]